We thus analysed the expression of several well studied inhibitory molecules and found that CTLA-4, PD-1, PD-L1, PD-L2, CD276 and PVR were upregulated in breast cancer patients with mtp53 (Fig. 4a). Here, CD276 is linked to breast carcinoma.